302 related articles for article (PubMed ID: 17962609)
21. [Adjuvant treatment of breast cancer. Endocrine therapy].
Mouridsen HT; Andersen J
Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
[TBL] [Abstract][Full Text] [Related]
22. Advances in adjuvant endocrine therapy for postmenopausal women.
Lin NU; Winer EP
J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
[TBL] [Abstract][Full Text] [Related]
23. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
24. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
[TBL] [Abstract][Full Text] [Related]
25. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
[TBL] [Abstract][Full Text] [Related]
26. Current controversies in extended adjuvant endocrine therapy for early breast cancer.
Snoj N; Paridaens R; Cufer T
Curr Opin Oncol; 2008 Nov; 20(6):627-33. PubMed ID: 18841043
[TBL] [Abstract][Full Text] [Related]
27. [Neoadjuvant antihormonal treatment of women with breast cancer].
Tuxen MK; Kamby C; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L;
Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
[TBL] [Abstract][Full Text] [Related]
29. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].
Petráková K; Nenutil R; Grell P; Fabian P; Zichová I; Svoboda M; Palácová M; Vyzula R
Klin Onkol; 2008; 21(5):303-8. PubMed ID: 19202962
[TBL] [Abstract][Full Text] [Related]
30. Extending the benefits of adjuvant therapy in early HR+ breast cancer.
Goss PE
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():45-52. PubMed ID: 18785006
[TBL] [Abstract][Full Text] [Related]
31. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
Abdulhaq H; Geyer C
Am J Clin Oncol; 2008 Dec; 31(6):595-605. PubMed ID: 19060594
[TBL] [Abstract][Full Text] [Related]
32. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
Okunade G; Green AR; Ying M; Agrawal A; Paish EC; Aleskandrany M; Winterbottom L; Hassell K; Morgan DA; Ellis IO; Cheung KL
Crit Rev Oncol Hematol; 2009 Oct; 72(1):76-82. PubMed ID: 19515574
[TBL] [Abstract][Full Text] [Related]
33. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
[TBL] [Abstract][Full Text] [Related]
34. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
Toi M; Yamashiro H; Tsuji W
Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
[TBL] [Abstract][Full Text] [Related]
35. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
36. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
Colomer R; Llombart-Cussac A; Lloveras B; Ramos M; Mayordomo JI; Fernández R; Tusquets I; Gil M; Barnadas A; Constenla M; Gilabert M; Alba E
Cancer; 2007 Nov; 110(10):2178-85. PubMed ID: 17926331
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
[TBL] [Abstract][Full Text] [Related]
38. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
[TBL] [Abstract][Full Text] [Related]
39. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
Ewer MS; Glück S
Cancer; 2009 May; 115(9):1813-26. PubMed ID: 19235248
[TBL] [Abstract][Full Text] [Related]
40. Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study.
Schrading S; Schild H; Kühr M; Kuhl C
Radiology; 2014 Apr; 271(1):45-55. PubMed ID: 24475835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]